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The NRF2/sMAF protein complex regulates the
oxidative stress response by occupying cis-acting
enhancers containing an antioxidant response
element (ARE). Integrating genome-wide maps of
NRF2/sMAF occupancy with disease-susceptibility
loci, we discovered eight polymorphic AREs linked
to 14 highly ranked disease-risk SNPs in individuals
of European ancestry. Among these SNPs was
rs242561, located within a regulatory region of the
MAPT gene (encoding microtubule-associated pro-
tein Tau). It was consistently occupied by NRF2/
sMAF in multiple experiments and its strong-binding
allele associated with higher mRNA levels in cell lines
and human brain tissue. Induction of MAPT tran-
scription by NRF2 was confirmed using a human
neuroblastoma cell line and a Nrf2-deficient mouse
model. Most importantly, rs242561 displayed com-
plete linkage disequilibrium with a highly protective
allele identified in multiple GWASs of progressive
supranuclear palsy, Parkinson’s disease, and corti-
cobasal degeneration. These observations suggest
a potential role for NRF2/sMAF in tauopathies and
a possible role for NRF2 pathway activators in dis-
ease prevention.INTRODUCTION
Identifying genetic variants that play amechanistic role in human
disease is critical for better understanding the origins, progres-
sion, and treatment of diseases and for identifying biomarkers
that could reveal individuals at increased risk for developing830 Cell Reports 15, 830–842, April 26, 2016 ª2016 The Authors
This is an open access article under the CC BY-NC-ND license (http://disease. Genome-wide association studies (GWASs) have iden-
tified approximately 2,000 SNPs significantly (p < 5 3 108)
associated with susceptibility to more than 70 human diseases
(Welter et al., 2014). However, differentiating the causal SNPs
responsible for the disease association from the many non-func-
tional, associated SNPs has been difficult. Large-scale initiatives
such as the Encyclopedia of DNAElements (ENCODE) (ENCODE
Project Consortium, 2012) and the Roadmap Epigenomics
Project (Kundaje et al., 2015) have mapped catalogs of regula-
tory regions, including genome-wide occupancy of hundreds
of transcription factors (TFs) across dozens of cell lines using
ChIP-seq (chromatin immunoprecipitation sequencing). The
1000 Genomes Project has built a resource for determining ge-
netic linkage based on the sequenced genomes of 1,092 individ-
uals from 14 populations (Abecasis et al., 2012). Importantly,
about 80% of disease-associated SNPs identified in GWASs
are significantly enriched in non-coding functional DNA elements
identified by ENCODE (Schaub et al., 2012). We anticipate that
variants affecting TF binding in gene regulatory elements may
lead to downstream differences in gene expression and be the
underlying mechanism causing a disease phenotype. Recently,
integration of GWAS data with TF occupancy has strongly sup-
ported a role for polymorphic transcriptional regulatory elements
in the risk of cancer (Zeron-Medina et al., 2013) and other dis-
eases (Fogarty et al., 2014; Karczewski et al., 2013; Maurano
et al., 2012; Schaub et al., 2012). Furthermore, incorporating
eQTL (expression quantitative trait loci) information frommultiple
tissues into the analysis of GWAS results can provide functional
support, linking SNPs that affect gene expression with disease
risk (Dubois et al., 2010; Farh et al., 2015).
The TF NRF2 (nuclear factor, erythroid 2 like 2 [NFE2L2]) is the
‘‘master regulator’’ of the cellular antioxidant response to oxida-
tive or electrophilic stress. Under basal conditions, NRF2 resides
mainly in the cytoplasm bound to its cysteine-rich, Kelch-
domain-containing partner KEAP1, which is anchored to the
actin cytoskeleton and regulates ubiquitination and degradationcreativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Study Design and Summary of Candidates
(A) Overview of workflow for identifying functional ARE SNPs associated with
disease.
(B) The significance of GWAS SNPs linked to ARE SNPs.of NRF2. Reactive oxygen species (ROS) or NRF2 pathway ac-
tivators modify cysteine residues of KEAP1, leading to confor-
mational change and disrupting the KEAP1-NRF2 complex.
Thus, NRF2 accumulates, translocates to the nucleus, and het-
erodimerizes with bZIP proteins such as small MAF proteins
(sMAF, e.g., MAFG, MAFF, and MAFK) to form a transactivation
complex that binds to antioxidant response elements (AREs)
(Rushmore et al., 1991; Tong et al., 2006; Wakabayashi et al.,
2004). These cis-acting enhancer ARE sequences are found in
the promoter or enhancer regions of many genes encoding anti-
oxidant and phase II detoxification enzymes/proteins (Hayes and
McMahon, 2001; Itoh et al., 1997). In addition, NRF2 binds AREs
in genes that participate in diverse processes such as immune
and inflammatory responses, metabolism, tissue remodeling
and fibrosis, metastasis, cognitive dysfunction, and addictive
behavior (Hayes and Dinkova-Kostova, 2014). Thus, dysregula-tion of NRF2-regulated genes could provide a plausible explana-
tion for the connections between oxidative stress and numerous
human diseases (Hybertson and Gao, 2014), including chronic
neurological diseases (Yamazaki et al., 2015). The functional
ARE bound by NRF2 is represented as the consensus sequence
50-TMAnnRTGAYnnnGCR-30, whereM=A or C; R = A or G; Y =C
or T, and the ‘‘core’’ consensus is underlined (Nioi et al., 2003;
Wasserman and Fahl, 1997). Recently, a large number of
genomic regions occupied by NRF2 and small MAF proteins
have been discovered using ChIP-seq (Chorley et al., 2012;
ENCODE Project Consortium, 2012). Despite the progress in
identifying ARE target genes, little is known about how poly-
morphisms might affect their function and impact disease
susceptibility.
In this report, using linkage disequilibrium (LD) (the non-random
association between alleles at two genome locations) data from
the 1000 Genomes Project to enable integration of datasets, we
combined genome-wide maps of NRF2/sMAF occupancy with
disease risk SNPs identified inGWASs. This allowed identification
of genetic variants located in functional AREsand associatedwith
diseases. We then integrated diverse functional datasets to
provide evidence that several ARE SNPs affect NRF2-regulated
transcription, particularly the MAPT gene. From our analysis, we
propose a plausible oxidative stress-based mechanism for an
ARE SNP inMAPTmediating parkinsonian diseases.
RESULTS
Functional Antioxidant Response Elements Link to the
Strongest GWAS SNPs in Several Human Diseases
Numerous mouse model studies implicate Nrf2 as a susceptibil-
ity factor in a broad range of oxidative-stress-related pathologies
(Cho and Kleeberger, 2015; Hybertson and Gao, 2014; Johnson
and Johnson, 2015), suggesting that SNPs affecting human
functional NRF2 binding sites (e.g., AREs) could affect risk of
many diseases. Thus, we sought to detect GWAS disease
SNPs or their proxies (i.e., highly correlated SNPs in LD with a
GWAS SNP) that reside in genomic regions occupied by NRF2
and/or small MAF proteins and that contain a strong ARE motif.
To explore this possibility, we implemented a data analysis pipe-
line (Figure 1A) to integrate multiple genome-wide datasets and
to select candidates with functional evidence.
To reduce false positives, we used a stringent significance cut-
off (p% 5 3 108) for GWAS SNPs and considered only studies
with large population sizes (R1,000 individuals with European
ancestry [EUR]). We found 1,016 GWAS SNPs reported to be
associated with 80 different diseases in 134 individual studies,
and we identified 13,027 additional SNPs (or proxies) that were
in ‘‘complete LD’’ (r2R 0.95 in EUR) with the GWAS SNPs. We
refer to these GWAS SNPs and proxies as risk SNPs. To assess
which of these risk SNPs reside in NRF2/sMAF-occupied
genomic regions, we integrated NRF2/sMAF ChIP-seq data
derived from 15 unique experiments in eight cell types (listed in
Table S1). Included among these experiments were two we
generated previously using lymphoblastoid cells treated with
vehicle or with 10 mM sulforaphane (SFN) (Chorley et al., 2012),
a potent activator of NRF2 and upregulator of the antioxidant
response pathway.Cell Reports 15, 830–842, April 26, 2016 831
There were 9,852 NRF2 peaks reproducible in at least two ex-
periments. Together with the reproducible ENCODE ChIP-seq
peaks for MAFF (15,602) andMAFK (45,907), a total of 51,573 in-
dividual ChIP-seq peaks were observed from one or more TFs
(Figure S1A). We confirmed that the top enriched motif in
NRF2 ChIP-seq was also highly enriched in both MAFF and
MAFK ChIP-seq, and the sequence logos were highly similar
(p% 3.03 1004; by Tomtom; Machanick and Bailey, 2011; Fig-
ure S1B). By intersecting the reproducible ChIP-seq peaks with
GWAS data, we were able to determine that 94 SNPs reside in
genomic regions occupied by NRF2/sMAF and are linked to dis-
ease risk (Table S2). To further evaluate which of these 94 SNPs
also reside in a putative binding site (ARE), the sequences sur-
rounding these SNPs were analyzed by position weight matrix
(PWM) calculations (Wang et al., 2007). We determined that 14
SNPs reside in occupied AREs with PWM scores R6.4 (the
lowest PWM score among known AREs). These 14 ARE SNPs
link to 21 unique GWAS SNPs (Table 1; Figure 1B).
To assess the relative contribution of these ARE SNPs among
the linked diseases, the GWAS SNPs (Table 1, column 7) linked
with ARE SNPs were ranked by p values in their corresponding
original studies. We found that 14 of the 21 (67%) GWAS SNPs
were ranked among the top five most-significant SNPs (herein
we referred to as ‘‘highly ranked GWAS SNPs’’). Among them,
four were identified as having very significant p values and being
replicated in multiple studies. Sorting by GWAS p value, the
most-significant SNP rs8070723, located in an intragenic region
of the MAPT gene, associated with reduced risk of progressive
supranuclear palsy (PSP) (p = 1.53 10116), Parkinson’s disease
(p = 7.03 1012), and corticobasal degeneration (p = 1.33 108).
Other highly rankedGWASSNPswere rs8043757and rs9939609,
located in introns of the FTO gene, associated with risk of obesity
(p = 5.03 10110 and 1.93 10105, respectively). In addition, the
ARE SNP rs6426833, located in an intergenic region between
OTUD3 andRNF186, is a highly ranked GWAS SNP for ulcerative
colitis (p = 2.03 1068) that was replicated in five studies.
The Disease Signature of ARE SNPs Is Specifically
Defined by NRF2/sMAF Binding
We observed a surprising pattern, or signature, of highly ranked
GWAS SNPs displaying linkage with occupied ARE SNPs (Ta-
ble 1), and this is consistent with the general hypothesis put forth
by ENCODE that SNPs associated with disease tend to be en-
riched in TF-binding regions of open chromatin (ENCODEProject
Consortium, 2012). We posit that this observed disease risk
signature of ARE SNPs is due to occupancy by NRF2/sMAF
upon an ARE motif. To assess this, we selected highly ranked
SNPs and their proxies from 12 GWASs for the nine diseases
listed in Table 1 and then we first asked whether NRF2/sMAF-
bound ARE SNPs in the genome were more likely to be found
(i.e., enriched) among highly ranked GWAS SNPs than ARE
SNPs not bound by NRF2/sMAF. Using the PWM calculation to
assess the binding strength of the ARE, we determined that
2,641 SNPs reside in AREs with PWM scores R6.4 and were
reproducibly occupied by NRF2/sMAF in ChIP-seq experiments.
Among these 2,641 occupied ARE SNPs, there were eight ARE
SNPs associated with highly ranked GWAS SNPs (marked ‘‘a’’
in Table 1). However, among the unbound ARE SNPs that were832 Cell Reports 15, 830–842, April 26, 2016not in LD with occupied ARE SNPs in the genome, only 9 of
230,760 ARE SNPs were observed to be associated with highly
ranked GWAS SNPs. Therefore, the relative enrichment of
NRF2/sMAF-bound ARE SNPs among highly ranked GWAS
SNPswas 78-fold (8/2,641 versus 9/230,760) relative to unbound
ARESNPs (p=5.9031012; Fisher’s exact test). A similar enrich-
ment analysis against all risk SNPs found 203 ARE SNPs linked
with all risk SNPs and a 6-fold relative enrichment of NRF2/
sMAF-bound ARE SNPs among all risk SNPs (14/2,641 versus
203/230,760) relative to unbound ARE SNPs (p = 2.48 3 107).
This result provides strong support for a direct impact of NRF2/
sMAF occupancy among disease-associated SNPs.
We further asked whether SNPs located in any other putative
TF binding sites (TFBSs) identified as bound by ENCODE (159
TFs) displayed enrichment among highly ranked GWAS SNPs,
similar to that observed with NRF2/sMAF-bound ARE SNPs.
Among 147,994 occupied ENCODE TFBS SNPs (RegulomeDB)
that are not in LD with occupied ARE SNPs, we found only three
TFBS SNPs linked to highly ranked GWAS SNPs (SNP
rs1980781 linked to the risk SNP rs931520; rs6734363 linked
to the risk SNP rs6711012; rs7545115 linked to risk SNP
rs7538876). Therefore, compared to NRF2/sMAF-bound ARE
SNPs, the ENCODE-occupied TFBS SNPs were greatly
depleted (0.0067-fold; 3/147,994 versus 8/2,641; p = 1.39 3
1012; Fisher’s exact test) among highly ranked GWAS SNPs.
Similarly, there were 50 TFBS SNPs linked with all risk SNPs,
and the relative depletion of the ENCODE-occupied TFBS
SNPs among all risk SNPs was 0.064-fold (50/147,994 versus
14/2,641) relative to occupied ARE SNPs (p = 5.29 3 1012).
These comparisons reinforce that the risk signature of functional
ARE SNPs was defined by NRF2/sMAF occupancy and was in-
dependent of other TFBS SNPs identified in the ENCODE
project.
SNPs in Functional AREs Are Infrequent in the Genome
Using very stringent selection (reproducible ChIP-seq; LD r2 R
0.95; GWAS p % 5.0 3 108) criteria, our search was able to
identify only 14 functional ARE SNPs linked to disease risk
among 268,564 common (MAF R 1%) potential ARE SNPs in
the genome. We thus examined the possibility that functional
ARE SNPs are infrequent in the genome, possibly due to purify-
ing (negative) selection. We used the 15 NRF2/sMAF ChIP-seq
datasets and compared the frequency of occupied polymorphic
AREs to the frequency of polymorphic AREs never observed to
be occupied. In the genome, we identified 2,411,064 possible
AREs with a PWM score of 6.4 or greater (Figure S2A). Of these,
only 1.5% (35,659) of AREs were reproducibly occupied by
NRF2/sMAF in at least two and up to 15 different ChIP-seq ex-
periments. Presuming that occupancy in a multiplicity of exper-
iments indicates that a group of AREs would be more likely to be
functionally important, we calculated the frequency of SNPs in
the occupancy groups (shown in Figure S2A). Interestingly,
11.2% (265,747/2,375,405) of the non-occupied AREs contain
SNPs. The frequency declines in a monotonic way with
increased multiplicity of occupancy, from 8.0% (1,717/21,570)
in two to four experiments, 7.3% (591/8,049) in five to seven ex-
periments, 6.4% (320/5,023) in eight to ten experiments, to 6.0%
(61/1,017) in 11–15 experiments (Figure S2B). This decreased
Table 1. ARE SNPs and Their Linked Disease-Risk SNPs
ARE SNP
Allele ChIP-Seq Nearest Gene GWAS
Disease p Value
Rank in
PUBMED(PWM) NRF2 MAFF MAFK (Location) SNP GWAS
rs242561a T(19.7) C(17.6) 6 2 6 MAPT (intron) rs8070723 progressive
supranuclear palsy
1.50E116 1 21685912
rs8070723 Parkinson’s disease 7.00E12 2 21044948
rs8070723 corticobasal
degeneration
1.30E8 1 26077951
rs1981997 interstitial lung
disease
9.00E14 4 23583980
rs241032a C(15.4) T(10.5) 4 CRHR1-IT1
(downstream)
rs2942168 Parkinson’s disease 1.00E28 2 21292315
rs393152 Parkinson’s disease 2.00E16 1 19915575
rs62033400a A(7.1) G(7.0) 2 FTO (intron) rs8043757 obesity 5.00E110 1 23563607
rs7185735 obesity 1.00E79 3 23563607
rs17817449 obesity 2.00E12 1 21552555
rs9939609 obesity 1.90E105 1 25104851
rs9939609 obesity 4.90E74 1 19079261
rs9939609 type 2 diabetes 1.00E20 3 22693455
rs8050136 type 2 diabetes 2.00E17 2 19056611
rs8050136 type 2 diabetes 7.00E14 3 17463249
rs8050136 type 2 diabetes 1.00E12 3 17463248
rs9936385 type 2 diabetes 1.00E12 9 24509480
rs17817449 breast cancer 6.00E14 29 23535729
rs6426833a A(12.0) G(7.0) 5 RNF186 (upstream) rs6426833 ulcerative colitis 2.00E68 2 23128233
rs6426833 ulcerative colitis 4.00E35 2 21297633
rs6426833 ulcerative colitis 2.00E21 1 20228799
rs6426833 ulcerative colitis 5.00E13 2 19122664
rs6426833 ulcerative colitis 2.00E11 3 19915572
rs9603754 C(7.8) G(6.6) 2 LINC00598 (intron) rs941823 inflammatory
bowel disease
2.00E14 46 23128233
rs941823 ulcerative colitis 4.00E12 23 21297633
rs17035378 A(14.9) G(14.4) 2 2 PLEK (intron) rs17035378 celiac disease 8.00E09 24 20190752
rs12638492 A(7.7) G(7.6) 2 ILDR1 (intron) rs4285028 multiple sclerosis 2.00E08 45 21833088
rs6426519a G(9.5) A(7.4) 4 RHOU (downstream) rs801114 basal cell carcinoma 2.00E13 4 24403052
rs801114 basal cell carcinoma 6.00E12 2 18849993
rs16857611 A(7.8) G(2.9) 3 2 5 DIRC3 (intron) rs16857609 breast cancer 1.00E15 24 23535729
rs13067040 A(8.9) G(7.5) 2 MIR944
(downstream)
rs710521 bladder cancer 2.00E11 6 24163127
rs710521 bladder cancer 2.00E10 7 20972438
rs369184a A(10.3) G(5.4) 1 6 TEX14 (intron) rs9905704 testicular germ
cell tumor
4.00E13 2 23666239
rs9905704 testicular germ
cell tumor
3.00E09 9 23666240
rs4818832 G(11.6) A(11.4) 2 3 YBEY (intron) rs2839186 testicular germ
cell tumor
1.00E09 8 23666240
rs9884209a A(20.1) G(18.8) 1 2 SMARCAD1
(downstream)
rs17021463 testicular germ
cell tumor
1.00E08 5 23666239
rs62094906a C(11.6) T(7.9) 3 LOC101927571
(downstream)
rs11661542 intracranial aneurysm 1.00E12 2 20364137
See also Table S2.
aLinked to top five GWAS risk SNP.
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Table 2. Allele-Specific Binding Detected in ChIP-Seq Experiments
SNP Allele 1 PWM1 Allele 2 PWM2
Allele Counts
TF (Antibody) Cell p ValueA C G T
rs6426833 A 12 G 7 31 0 3 0 MAFK H1-hESC 7.66 3 107
61 0 23 0 MAFK MCF7 4.08 3 105
rs16857611 A 7.8 G 2.9 0 12 1 30 NFE2L2 A549 0.0054
0 44 0 89 MAFK A549 1.18 3 104
rs9884209 A 20.1 G 18.8 0 29 0 40 MAFK (SC-477) HepG2 ns
1 85 0 72 MAFK (ab50322) HepG3 ns
0 20 0 10 MAFK (ab50322) IMR90 ns
0 41 0 43 MAFK (ab50322) A549 ns
0 24 0 24 MAFF HepG2 ns
rs62033400 A 7.1 G 7 19 0 6 0 MAFK A549 0.0146
rs242561 T 19.7 C 17.6 0 22 0 38 MAFK H1-hESC 0.052
ns, not significant. See also Table S4.frequency of SNPs in AREs that display NRF2/sMAF occupancy
(p < 2.2 3 1016; Cochran-Armitage trend test) lends support to
the hypothesis that polymorphisms in functional AREs are sup-
pressed in human populations through negative evolutionary
selection.
Disease-AssociatedARE SNPsAre Frequently Occupied
by NRF2/sMAF in an Allele-Specific Manner
To explore the prediction that NRF2/sMAF could occupy AREs in
an allele-specific manner, we examined the sequence reads
generated from the ChIP-seq experiments in greater detail. For
each SNP position, we defined allele-specific binding as (1) at
least 20 sequencing reads overlapping a SNP position with the
least occupied allele having at least three reads and (2) one allele
having more reads than the other allele (p% 0.05 by exact bino-
mial test). This analysis requires that the cells used in the exper-
iment must be heterozygous for the SNP to be tested. Given this
limitation, among our 14 ARE SNPs, we found only five SNPs in
11 ChIP-seq experiments had enough reads for testing allele-
specific binding (Table 2). Despite this, we identified four SNPs
displaying significant allele-specific binding, including the three
SNPs linked to the most-significant GWAS risk SNPs. The differ-
ence in allele-specific binding was consistent with the predicted
binding strength assessed by PWM value, supporting the hy-
pothesis that higher PWM alleles should display greater occu-
pancy. This result provides corroboration that the disease-risk
AREs we identified are frequently occupied by NRF2/sMAF in
an allele-specific manner.
Disease-Linked ARE SNPs Are Enriched among ARE
SNPs Associated with Proximal Gene Expression
Disease-associated SNPs that affect NRF2/sMAF binding to
AREs under basal or induced levels of oxidative stress should
perturb the expression of adjacent genes,whichwould ultimately
influence phenotype and disease risk. To assess this, we took
advantage of many independent studies identifying eQTL in
various cells or tissues and examined the overlap between our
candidate SNPs and published significant eQTL signals. We
queried 2,641 NRF2/sMAF-occupied ARE SNPs and their prox-834 Cell Reports 15, 830–842, April 26, 2016ies against 16 eQTL datasets (listed in Table S3) to determine
whether theywere repeatable eQTLSNPs (i.e., replicable eSNPs)
that are in the top5%by false discovery rate (FDR) and<200 kb to
a nearby transcription start site (TSS).We found that 16.9% (446/
2,641)were repeatable, being associatedwithgeneexpression in
at least two of the queried datasets, either the same gene, or
adjacent genes. However, only 11.2% (25,736/230,760) of un-
bound AREs were replicable eSNPs, which indicated occupied
ARE SNPs were enriched for eSNPs (p value < 2.2 3 1016 by
chi-square test). In addition, we divided all ARE SNPs based on
‘‘bound’’ and ‘‘eSNP’’ and then analyzed the ratio of ARE SNPs
linked with risk SNPs to ARE SNPs not linked with risk SNPs.
We compared this ratio for ‘‘not bound, not eSNP’’ (0.057%;
116/204,908) to ‘‘not bound, eSNP’’ (0.343%; 88/25,648; 6.0-
fold enrichment, p < 2.2 3 1016); ‘‘bound, not eSNP’’ (0.366%;
8/2,187; 6.4-fold enrichment, p = 5.7 3 105); and ‘‘bound,
eSNP’’ (1.363%; 6/440; 23.9-fold enrichment; p = 3.1 3 107).
This significant enrichment supports our hypothesis that NRF2/
sMAF-occupied ARESNPs that are associatedwith transcription
are more likely to be linked to disease risk.
A Functional ARE SNP in MAPT Intron 1 Is a Strong
Candidate as a Causal SNP in Progressive Supranuclear
Palsy, Parkinson’s Disease, and Corticobasal
Degeneration
Considering more deeply the available functional evidence and a
plausible underlying molecular mechanism, we propose an ARE
SNP in the first intron of MAPT gene (encoding microtubule-
associated protein tau) may explain a portion of the genetic sus-
ceptibility to parkinsonian diseases. First, this SNP rs242561
(previously known as rs113166067) located at chr17:44026548
(hg19) was consistently occupied by NRF2, MAFF, and MAFK,
as measured by ChIP-seq (Figure 2A), and was located at the
peak of the strongest binding signals in multiple experiments
(Figure 2A). Specifically, 14 of 15 available ChIP-seq peaks over-
lap this SNP, which includes six NRF2 ChIP-seq, two MAFF
ChIP-seq, and six MAFK ChIP-seq experiments performed in
eight different cell lines. The homologous sequence in themouse
was also bound in both Nrf2 and MafK ChIP-seq experiments
Figure 2. Characteristics of rs242561
(A) Location relative to risk SNP for PSP and PD and ChIP-seq signals.
(B) Position in ARE motif.
(legend continued on next page)
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Table 3. Allele-Specific Expression Detected in mRNA-Seq Experiments
GEO Time Point H1 H2a
Fold
Change
(H2/H1)
p Valueb
(H2/H1)
rs17650901
Allele 1
rs17650901
Allele 2c
rs1052551
Allele 1
rs1052551
Allele 2
rs17652121
Allele 1
rs17652121
Allele 2
GSE56785 hESC 9 16 1.8 0.23 6 12 3 4
NPC day 1 511 616 1.2 1.94 3 103 219 243 158 188 134 185
NPC day 2 36 53 1.5 0.09 14 22 13 23 9 8
NPC day 4 130 163 1.3 0.06 62 61 36 58 32 44
NPC day 5 200 212 1.1 0.59 76 84 75 70 49 58
NPC day 11 1487 1736 1.2 1.24 3 105 246 282 658 784 583 670
NPC day 18 64 59 0.9 0.72 29 25 15 15 20 19
GSE20301 N2_A 39 64 1.6 0.0176 8 7 19 51 12 6
N3_A 2 26 13.0 3.03 3 106 0 7 2 12 0 7
GSE16256 hESC 19 23 1.2 0.64 6 10 13 13
NPC 80 114 1.4 0.0176 35 53 33 47 12 14
aH2 is the sum of total reads overlapping allele 2 of SNPs rs17650901, rs1052551, and rs17652121.
bBinomial test.
cIn each case, allele 2 is the allele linked with the stronger binding T allele of rs242561 on haplotype H2.(Figure S3A). In addition, the Roadmap Epigenome project
chromHMM model classifies this genomic location in brain tis-
sue (substantia nigra) as an enhancer or as actively transcribed
(brain germinal matrix; hippocampus) and it is repressed in
most other non-brain tissues. These data along with the high
interspecies evolutionary conservation at this binding site (Fig-
ures 2B and 2C) strongly support a functional role for NRF2/
sMAF binding in neural brain tissues.
Second, this SNP is predicted to affect NRF2/sMAFK binding
and transactivation based on the PWM calculation. The T allele
(PWM = 19.7) confers a stronger binding ARE relative to the C
allele (PWM = 17.6; Figure 2D). Counting the alleles present in
sequence reads in the MAFK ChIP-seq in H1-hESC supports
the PWM prediction indicating the T allele is a stronger binding
ARE. Of the 60 unique sequencing reads precipitated with
MAFK antibodies, 61% contained the T allele (38) and 39% the
C allele (Figure 2D; T/C ratio = 1.7; p = 0.052; by binomial test).
The allele-specific binding was confirmed by NRF2 ChIP tag-
mentation sequencing, using a lymphoblastoid cell line (LCL)
(GM12763; heterozygous for rs242561) treated with SFN. We
found that the ratio of T/C alleles was 1.46 (47,274 reads versus
32,320 reads; averaged from three replicates; see also Table S4
and Figure S3B), showing significant difference in allele counts (p
value < 2.2 3 1016). We further evaluated the interaction be-
tween NRF2 and this binding sequence using reporter con-
structs containing the two alleles. Both constructs can be
strongly activated by NRF2 in IMR32 cells, and the stronger
binding T allele construct displays significantly higher (2-fold)
transactivation ability relative to theC allele construct (Figure 2E).(C) Conservation.
(D) Allele-specific binding.
(E) Allele-specific transactivation.
(F) RT-PCR of MAPT levels in human IMR32 neuroblastoma cells treated with t-B
(G)Nrf2 +/+ andNrf2/mice were exposed to oxidative stress induced by hype
by RT-PCR.
See also Figure S3 and Tables S4 and S5.
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confirmed using both a human neuroblastoma IMR32 cell line
that carries a homozygous C allele and a Nrf2-deficient mouse
model. In cells, treatment with 10-mM tert-butylhydroquinone
(t-BHQ) (a NRF2 activator) significantly increased MAPT mRNA
level 3.8-fold relative to vehicle DMSO (Figure 2F), although
IMR32 was not responsive to all NRF2 pathway activators.
When Nrf2+/+ and Nrf2 / mice were exposed to either air or
oxidative stress caused by hyperoxia,MaptmRNA in cerebellum
ofNrf2+/+mice treatedwith hyperoxia was significantly elevated
1.7-fold compared with air treatment, but Mapt mRNA in cere-
bellum of Nrf2/ mice had no significant change under either
treatment. Therefore, Mapt transcription in mouse cerebellum
has an Nrf2-dependent pattern (Figure 2G), as with known Nrf2
target genes Nqo1, Gclc, Gstm1, and Hmox1 (Table S5), indi-
cating the possible importance of Nrf2 in Mapt regulation under
oxidative stress conditions.
Third, this SNP affected MAPT transcription in an allele-spe-
cific manner in cells as measured by RNA-seq. Using polyA+
RNA-seq datasets (GSE56785, GSE20301, and GSE16256)
obtained from H1 embryonic stem cell (H1-hESC) and neural
progenitor cells derived from H1-hESC by different protocols,
we counted sequencing reads overlapping three MAPT exon
SNPs (rs17650901 on 50 UTR, rs1052551 on exon 7, and
rs17652121on exon 9) that are in complete LD with rs242561.
We found that the alleles linked with the stronger binding T allele
had a pattern of higher sequencing read counts (Table 3). Further
aggregating allele counts into counts per haplotype, we found
the haplotype linked with the stronger binding T allele hadHQ or vehicle.
roxia, andMapt gene expression level wasmeasured inmRNA from cerebellum
Table 4. The Association of Genotypes of ARE SNP rs242561 with MAPT mRNA Levels
Proxy/SNP LD (r2) Tissue Brain Region Probe ID Allelea Frequency Beta p Value Data Source Reference
rs17650579 0.97 adipose ILMN_2310814 T 0.24 0.135 1.90 3 1014 MuTHER Grundberg
et al., 2012
rs1981997 0.97 brain TCTX (temporal
cortex)
3723707 A 0.27 0.151 8.93 3 106 UKBEC Ramasamy
et al., 2014
rs242561 esophagus
mucosa
(RNA-seq) T NA 0.530 2.90 3 107 GTEx GTEx
Consortium,
2015
rs242561 brain CRBL (cerebellar
cortex)
3723710 T 0.27 0.195 1.37 3 105b UKBEC Ramasamy
et al., 2014
rs242561 brain TCTX (temporal
cortex)
3723707 T 0.27 0.153 9.78 3 106b UKBEC Ramasamy
et al., 2014
rs242561 brain TCTX (temporal
cortex)
3723751 T 0.27 0.197 1.78 3 105b UKBEC Ramasamy
et al., 2014
rs242561 brain WHMT (intralobular
white matter)
3723707 T 0.27 0.175 1.32 3 1005b UKBEC Ramasamy
et al., 2014
aThe allele linked with stronger binding.
bPassed Bonferroni correction for 2,197 SNPs genotyped in the 400-kb region centered by rs242561.consistently higher read counts (except for one time point in
GSE56785). Conditions or time points with higher levels of
expression generally displayed statistically significant differ-
ences between the two haplotypes (Table 3).
Fourth, the observation of rs242561-associated allele-specific
expression ofMAPT was further strengthened by examining hu-
man population datasets. Querying eQTL datasets, the geno-
types for rs242561 or proxies were significantly associated
with mRNA levels of the MAPT gene in three different tissues
(brain, subcutaneous fat [adipose], and esophagus mucosa),
asmeasured by Affymetrix exon array, Illumina Ref-8 bead array,
and RNA-seq, respectively (Table 4). Because microarray
probes containing SNPs in the sequences would confound
expression measurements, such as ILMN_1710903 or affy_
3723733 (Ramasamy et al., 2013; Trabzuni et al., 2012), we
excluded eQTLs measured with SNP-containing probe sets.
As listed in Table 4, a significant association was reported be-
tween rs242561-linked SNP rs17650579 and MAPT mRNA
levels measured by ILMN_2310814 in adipose tissue among
850 European descendants (Grundberg et al., 2012). The T allele
of rs17650579 is in complete LD (r2 = 0.97; Figure 3A) with the
stronger binding T allele of rs242561 and was associated with
higher MAPT expression. Similarly, in the UK Brain Expression
Consortium (UKBEC) study (Ramasamy et al., 2014), a signifi-
cant association was reported between the A allele of
rs1981997 and higherMAPTmRNA levels in brain tissue among
134 European descendants free of neurodegenerative disorders.
The A allele of rs1981997 is in complete LD (r2 = 0.97; Figure 3A)
with the stronger binding T allele of rs242561. In theGTEx project
data, the stronger binding T allele of rs242561 (previously
known as rs113166067) was associated with higher RNA-seq-
measured MAPT expression in esophagus mucosa from 95
individuals (GTEx Consortium, 2015).
We further downloaded the UKBEC dataset from http://www.
braineac.org to examine the effect of rs242561 genotype on
MAPT expression levels in different regions of the brain among143 healthy individuals. We confirmed that the stronger binding
T allele of rs242561 (chr17: 44026548) was associated with the
higherMAPTmRNA levels in three different regions in brain (Ta-
ble 4), including cerebellar cortex (CRBL), temporal cortex
(TCTX), and intralobular white matter (WHMT), after Bonferroni
correction (p = 1.28 3 105) for 2,197 genotyped SNPs within
400-kb region centered on rs242561. This trend was consistent
with our PWM prediction. Figure 3B displays rs242561 geno-
types and mRNA levels in brain TCTX region from UKBEC sub-
jects measured by three different Affymetrix Exon 1.0 ST probe
sets targeting exon 1 by 3723707, exon 2 by 3723710, and 30
UTR by 3723751. The stronger binding T allele corresponds to
higherMAPTmRNA for all three probe sets. Similarly, the protec-
tive G allele of rs8070723 corresponds to higherMAPTmRNA for
all three probe sets (Figure S3C). In addition, probe set 3723712,
marking expression of exon 3, showed a similar pattern (Fig-
ure S3D), although its expression level was lower than the above
three probes. To exclude the possibility that other potential TFBS
SNPs might affect this relationship, we searched the HaploReg
database (Ward and Kellis, 2012) against all SNPs that were in
complete LD (r2 = 1) with rs242561 and found no SNPs among
other reproducibly occupied TFBSs with matched TF motifs.
Last andmost importantly, as previously mentioned, we found
this SNP rs242561 was in complete LD (r2 = 0.96; Figure 3A) with
rs8070723, the strongest GWAS signal (p = 1.53 10116; Ho¨glin-
ger et al., 2011) for PSP, and very strong signal for Parkinson’s
disease (p = 7.0 3 1012; Spencer et al., 2011), corticobasal
degeneration (p = 1.33 108; Kouri et al., 2015), and Alzheimer’s
(p = 5.2 3 105; Allen et al., 2014). The stronger NRF2/sMAF-
binding allele T (corresponding to high MAPT expression) of
rs242561, which enhances MAPT expression, is in complete
LD with the G allele of rs8070723 (frequency = 0.23 and 0.05 in
control and case, respectively) that confers a protective effect
in Europeans with an odds ratio of 0.18, indicating a 5.11-fold
lower risk for PSP, which is the largest odds for protective effect
identified among all disease GWASs. Similarly, this G allele wasCell Reports 15, 830–842, April 26, 2016 837
Figure 3. Association of rs242561 Genotypes with MAPT mRNA Levels in Humans
(A) Map of rs242561 and eQTL SNPs with LD correlations (R2) within the MAPT gene.
(B) MAPT mRNA levels and genotypes of rs242561 in human brain TCTX as measured by Affymetrix Exon array (UKBEC). TT is the stronger binding genotype.
See also Figure S3.associated with the protection of Parkinson’s, corticobasal
degeneration, and Alzheimer’s diseases. Thus, we propose
that the stronger NRF2/sMAF-binding T allele of rs242561 leads
to the higher MAPT expression and is a functionally protective
allele for parkinsonian disorders in European ancestry
populations.
DISCUSSION
Recent studies using integrated analysis of genome-wide data
have identified SNPs affecting allele-specific TF occupancy
that can be mechanistically linked with a disease (Fogarty et al.,
2014; Karczewski et al., 2013; Maurano et al., 2012; Schaub
et al., 2012; Zeron-Medina et al., 2013). Here, we focused on838 Cell Reports 15, 830–842, April 26, 2016the gene network regulated by NRF2 and its binding partners
(MAFF and MAFK). Activation of NRF2, either genetically or
with chemical activators, such as SFN and t-BHQ, protects a
broad range of tissues, including neurological, from oxidative-
stress-related toxicity by upregulating antioxidant response
genes (Hayes and Dinkova-Kostova, 2014; Yamazaki et al.,
2015). Knockout ofNrf2 (Nrf2/mice) directly increases oxida-
tive-stress-related neurological damage (Yamazaki et al., 2015)
with associated behavioral outcomes and neurotransmitter func-
tion (Muramatsu et al., 2013). Interestingly, recent work has
demonstrated thatNrf2 activation inP301Smiceprotects against
oxidative stress and tau-related neurotoxicity (Stack et al., 2014).
However, until the present study, no one has directly connected
MAPT (tau) expression with NRF2/sMAF binding.
We hypothesize that the stronger binding T allelic variant of
rs242561, which occurs on the H2 1-Mb inversion haplotype,
brings MAPT transcription under stronger regulation by NRF2/
sMAF. The H2 haplotype (T allele) is associated with higher levels
ofMAPTmRNA as observed in numerous studies (Caffrey et al.,
2008; Ramasamy et al., 2014; Trabzuni et al., 2012). The MAPT
Tau protein has seven major isoforms formed by alternative
splicing of exons 2, 3, and 10, and it has been reported that
the H2 haplotype encoded mRNA andMAPT Tau protein display
higher levels of inclusion of MAPT exon 3 relative to H1 haplo-
types (Trabzuni et al., 2012). Inclusion of exon 3 in the Tau protein
has been demonstrated to be protective, decreasing both pro-
pensity for aggregation (Zhong et al., 2012) and amyloid-beta
toxicity in a mouse model of Alzheimer’s disease (AD) (Ittner
et al., 2011). For those individuals who carry the rs242561 T allele
that is present on the H2 haplotype, NRF2/sMAF regulation of
the MAPT gene should result in production of a Tau protein
that resists aggregation and is protective against tauopathies
like PSP and PD. Abnormal hyperphosphorylation and aggrega-
tion of MAPT is a critical molecular feature that characterizes
tauopathies, for which the mechanism is unknown (Ballatore
et al., 2007).
It is unclear whether in vivo regulation of human MAPT by
NRF2/sMAF is a basal effect or is induced by oxidative stress.
We observed NRF2-dependent regulation of MAPT in neural
cells in culture and in cerebellum in aNrf2mouse oxidative stress
model; however, neither of these models have the H2 haplotype
and the T allele of rs242561. We suggest that individuals
harboring the T allele of the ARE SNP rs242561 could benefit
froman upregulation of aggregation resistant, exon-3-containing
Tau protein, especially under conditions of oxidative stress. This
would presumably lead to the observed protective effect of this
allele. It seems likely that, in parallel, upregulation of other NRF2
targets (NQO1 and HMOX1) would also occur, reducing oxida-
tive stress and promoting degradation of aggregated proteins
(SQSTM1).
Studies of eQTLs in the MAPT gene have been controversial
due to several publications identifying false-positive eQTLs re-
sulting from SNPs in array probe sequences interfering with
expression measurement (Ramasamy et al., 2013). Combined
with an extremely complex gene locus structure that includes a
1-Mb inversion haplotype, termed H2, as well as copy number
variation, the literature on this topic presents a confusing picture
of the relationship between polymorphic variants and Tau
expression and subsequent PSP/Parkinson’s risk. Some pub-
lished eQTL reports have suggested that the H1 haplotype
(risk alleles) is associated with higher MAPT expression and
that consequent hyperphosphorylation of MAPT drives risk
(Gibbs et al., 2010; Myers et al., 2007; Zou et al., 2012). However,
these reports have consistently measured mRNA expression
using an array probe (e.g., ILMN_1710903) containing a 2-bp
deletion polymorphism (Ramasamy et al., 2013), and this probe
fails to detect mRNA transcribed from the H2 haplotype. Using
an H1/H2 haplotype-specific expression assay based on a
50 UTR SNP rs17650901 (in complete LD with rs242561) to
compare N-terminal exon expression in a heterozygous H1/H2
human neuronal cell culture model and in post-mortem human
brain tissues from 14 control individuals, the protective MAPTH2 haplotype was found to have 2-fold more MAPT transcripts
(containing exons 2+3+) than the disease-associated H1 haplo-
type (Caffrey et al., 2008). The H2 haplotype was also associated
with higher expression of exon 3 (as detected by Affymetrix
probe set 3723712) in all brain regions except white matter in
439 control individuals (Trabzuni et al., 2012). In addition, higher
MAPTmRNA level was associated with SNP alleles on the same
H2 haplotype with rs242561 T allele including the minor A allele
of rs1981997 (r2 = 0.97 with rs242561; Ramasamy et al., 2014)
and the minor A allele of rs113986870 (r2 = 0.82 with
rs242561), which is associated with reduced risk of Alzheimer’s
disease (Jun et al., 2016). Altogether, it seems clear from previ-
ous studies and the present study that the H2 haplotype and
theMAPT ARE SNP rs242561 T allele are associated with higher
MAPT mRNA expression and are protective in tau-associated
pathologies, including PSP, a rare parkinsonian disorder, and
Parkinson’s disease. Interestingly, in AD, the H2-haplotype-
tagging rs8070723 G allele (coupled with rs242561 T allele)
was also associated with reduced risk, but in diseased brain,
MAPT levels were lower in the cerebellum and TCTX (Allen
et al., 2014; Zou et al., 2012). However, in these studies of AD
brains, MAPT mRNA level was measured by probe ILMN_
2298727, which was not robustly detected in normal human
brain samples (Trabzuni et al., 2012).
The protective H2 haplotype (high expression allele), which
occurs at a frequency of 0.2 in European ancestry populations
but is nearly absent in Africans and Asians, may have undergone
positive selection in Europeans (Stefansson et al., 2005). We
suggest that NRF2/sMAF-driven, higher levels of the MAPT
isoform containing exon 3 may protect glia from pathological
damage to the tau protein that may occur under conditions of
oxidative stress, and this may be a plausible mechanism for
both the protective effect in disease and positive selection.
We have used an integrated approach to combine genome-
wide maps of NRF2/sMAF occupancy with disease risk signals
identified in GWASs to find potential functional AREs SNPs asso-
ciated with disease risk. We further integrate these data with
diverse transcriptional datasets to support the functional
connection between several ARE SNPs and NRF2-regulated
transcription. The data provide strong support for a link between
NRF2/sMAF occupancy at rs242561 in the MAPT gene, allelic
expression in neuronal cells, and parkinsonian disorders. As
shown inmany animalmodels of oxidative-stress-related pathol-
ogy, NRF2 activation via dietary components such as SFN is
protective; the present results suggest NRF2 activation might
be useful in prevention of neurological diseases such as PSP
and PD (Johnson and Johnson, 2015).EXPERIMENTAL PROCEDURES
ChIP-Seq Data
We used seven unique NRF2 ChIP-seq datasets in this study (Table S1),
generated in LCL, BEAS-2B, A549, HepG2, and K562. BEAS-2B and LCL
were treated with SFN or vehicle (Chorley et al., 2012). The raw reads were
aligned against human reference sequence (hg19) using Burrows-Wheeler
alignment (BWA) tool (Li et al., 2008). Peakswere called usingMACS2 program
(Zhang et al., 2008) with its default setting. Then, we only kept peaks that had a
FDR q value% 5% and had six or more reads at the summits. The MAFF and
MAFK ChIP-seq peaks were downloaded from the ENCODE DataCell Reports 15, 830–842, April 26, 2016 839
Coordination Center. The file name is wgEncodeRegTfbsClusteredV3.bed,
which was generated by the ENCODE AnalysisWorking Group using a uniform
processing pipeline (Li et al., 2011) for all 161 TFs. To provide reliable TF bind-
ing signals, we only selected peaks observed in two or more cell types for
further analysis. We further filtered out peaks overlapping the ENCODE black-
list (ENCODE Project Consortium, 2012).
GWAS Data
We use the National Human Genome Research Institute’s (NHGRI) GWAS
catalog (Welter et al., 2014; http://www.genome.gov/gwastudies, down-
loaded on September 9, 2014) to obtain a list of risk SNPs. The selection
criteria were discovered in studies with the ‘‘Disease/Trait’’ attribute matching
any human disease terms defined by MeSH (Medical Subject Headings)
from the National Library of Medicine, performed in Europeans, and with
p values < 5.0 3 108 and a population size 1,000 or more in either discovery
or replication phase. We discarded all GWAS SNPs mapped into any exon
regions.
SNP Sequence, Allele Frequency, and Linkage Disequilibrium Data
The SNP sequences were downloaded from NCBI dbSNP database (build
141). We selected SNPs with a minor allele frequency >1% in 379 Europeans
in the 1000 Genome project’s Phase I Integrated Release Version 2 (Abecasis
et al., 2012). The LD data were downloaded from http://csg.sph.umich.edu/
abecasis/MACH/download/1000G.2012-02-14.html.
eQTL Data
We selected 15 publicly available eQTL datasets that originated from gene
expression profiles under no treatment in healthy European descendants (Ta-
ble S3) that report cis SNP-gene associations in eight tissues/cells. The pop-
ulation size ranged from 134 to 5,311. We also selected the GTEx project
(GTEx Consortium, 2015) results on 12 tissues/cells with the sample
size R200. To focus on most-significant signals that may underlie regulation
of transcription, we selected eQTLs that were ranked top 5% by FDR, with a
distance to TSS <200 kb. To avoid false positive, we filtered out expression
probes that contained common SNPs (MAF R 1% in EUR panel of 1000
Genomes project).
Integrative Annotation of SNPs Based on Linkage Disequilibrium
We selected the GWAS SNPs related to disease risk from NHGRI GWAS
Catalog. Next, we extended GWAS SNP sets by identifying all SNPs in com-
plete LD (r2R 0.95) with a GWAS SNP in the EUR population of the 1000 Ge-
nomes Project. Then, comparing this set of disease risk SNPs with the SNPs
located in the ChIP-seq peaks, we identified SNPs bound by NRF2/sMAF
and linked to disease risk. For each of our candidate ARE SNPs linked to dis-
ease risk, we identified all SNPs in a complete LD (r2R 0.95) in the EUR pop-
ulation of 1000 Genomes Project. Then, comparing this set of ARE SNPs and
their proxies with the SNPs discovered by eQTL studies, we identified ARE
SNPs potentially affecting gene transcription.
Detection of Allele-Specific Binding and Allele-Specific Expression
After mapping ChIP-seq reads to hg19, the MPILEUP function in the Samtools
(Li et al., 2009) was used to pile up reads overlapping SNP positions. Then, we
identified heterozygous sites and used a binomial test to evaluate whether
there was a difference in read counts of tested alleles. After mapping RNA-
seq reads using STAR (v2.4.2a; Dobin et al., 2013) to hg19, the GATK (v3.4;
McKenna et al., 2010) was used to pile up reads overlapping SNP positions.
Then, we identified heterozygous sites and used a binomial test to evaluate
whether there was a difference in read counts of tested alleles.
Association of SNP Genotype and MAPT Expression
TheMAPT gene expression and SNP genotyping data were downloaded from
the UKBEC (http://www.braineac.org; Ramasamy et al., 2014; Trabzuni et al.,
2011). These data originate from brain tissue from 134 individuals free of
neurodegenerative disorders. Up to ten regions per brain were analyzed using
Affymetrix Exon 1.0 ST Array. To avoid false-positive association, the probe
sets were examined for common SNPs and indels (MAF > 1% in EUR) using
a web application called ‘‘polymorphism-in-probe finder (PiP Finder) tool’’840 Cell Reports 15, 830–842, April 26, 2016(https://caprica.genetics.kcl.ac.uk/ilori/pipfinder.php; Ramasamy et al.,
2013). We used 13 probe sets that had average log2-expression levels >7.0
(recommended by Affymetrix) across ten regions, including 3723707,
3723710, 3723722, 3723725, 3723731, 3723735, 3723740, 3723743,
3723746, 3723747, 3723749, 3723751, 3723753, and 3723754. The probe
set 372712 was below this level of expression but was examined due to its
specific role in identifying exon 3. The SNPs we tested were 2,197 SNPs
genotyped in the 400-kb region centered by rs242561. A SNP was considered
as associated with MAPT expression level only if p < 2.28 3 105 (i.e., 0.05/
2,197; Bonferroni correction).
Other Bioinformatics Analyses
To identify SNPs within putative NRF2/sMAF binding sites (AREs), we
used PWM calculations computed from 57 published AREs to analyze the
sequences surrounding these SNPs (Wang et al., 2007). To determine
whether a SNP was within other TFBSs, we downloaded SNP annotation file
RegulomeDB.dbSNP141.txt from the RegulomeDB (Boyle et al., 2012).
Then, we examined the selected SNPs for reproducible ChIP-seq signals
and matched binding motifs of the TF used in the ChIP-seq.
Statistical Methods
The binomial test was used to test allele-specific binding or expression. For
each SNP of interest, we tested the null hypothesis that the counts of the
two alleles occurred equally with no allele-specific binding or expression.
Fisher’s exact test and chi-square test were used for enrichment analysis to
calculate the significance of the difference between expected and observed
frequencies (or ratios). The Cochran-Armitage trend test was used to assess
for the presence of an association between a variable with two categories
and a variable with k categories. The null hypothesis is the hypothesis of no
trend, which means that the binomial proportion is the same for all levels of
the explanatory variable. Two-way ANOVA was used to test whether Mapt
transcription in mouse brain was influenced by the presence of Nrf2 under hy-
peroxia conditions. The t test was used to test the significance of the difference
inmeans between two groups of data (treatment versus control). Multiple com-
parisons were controlled by using Bonferroni correction (0.05/number of
tests).
Luciferase Reporter Assays
See Supplemental Experimental Procedures.
RT-PCR and qPCR
See Supplemental Experimental Procedures.
Nrf2 +/+, Nrf2 / Mouse Oxidative Stress Exposure Model
See Supplemental Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
three figures, and five tables and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2016.03.068.
AUTHOR CONTRIBUTIONS
D.A.B. and X.W. conceived and designed the experiments; M.R.C., S.E.L.,
H.-Y.C., B.N.C., M.W., and C.L.C. performed the experiments; X.W., D.A.B.,
S.R.K., G.L.B., and M.S. analyzed the data; and X.W. and D.A.B. wrote the
paper.
ACKNOWLEDGMENTS
This work was funded by the Intramural Research Program of National Institute
of Environmental Health Sciences, NIH (projects: Z01ES100475 and
Z01ES46008), the University of Minnesota Foundation (to M.S.), and the Lud-
wig Institute for Cancer Research (to G.L.B.). The authors would like to
acknowledge Dr. Shuangshuang Dai for Linux computing support; NIEHS
Epigenomics Core; NIEHS Animal Facility Core; and Dr. Jean Harry, NIEHS, for
technical advice and useful comments on the manuscript.
Received: December 16, 2015
Revised: February 26, 2016
Accepted: March 17, 2016
Published: April 14, 2016
REFERENCES
Abecasis, G.R., Auton, A., Brooks, L.D., DePristo, M.A., Durbin, R.M., Hand-
saker, R.E., Kang, H.M., Marth, G.T., and McVean, G.A.; 1000 Genomes
Project Consortium (2012). An integrated map of genetic variation from
1,092 human genomes. Nature 491, 56–65.
Allen, M., Kachadoorian, M., Quicksall, Z., Zou, F., Chai, H.S., Younkin, C.,
Crook, J.E., Pankratz, V.S., Carrasquillo, M.M., Krishnan, S., et al. (2014). As-
sociation of MAPT haplotypes with Alzheimer’s disease risk and MAPT brain
gene expression levels. Alzheimers Res. Ther. 6, 39.
Ballatore, C., Lee, V.M., and Trojanowski, J.Q. (2007). Tau-mediated neurode-
generation in Alzheimer’s disease and related disorders. Nat. Rev. Neurosci. 8,
663–672.
Boyle, A.P., Hong, E.L., Hariharan,M., Cheng, Y., Schaub,M.A., Kasowski, M.,
Karczewski, K.J., Park, J., Hitz, B.C., Weng, S., et al. (2012). Annotation of
functional variation in personal genomes using RegulomeDB. Genome Res.
22, 1790–1797.
Caffrey, T.M., Joachim, C., and Wade-Martins, R. (2008). Haplotype-specific
expression of the N-terminal exons 2 and 3 at the human MAPT locus. Neuro-
biol. Aging 29, 1923–1929.
Cho, H.Y., and Kleeberger, S.R. (2015). Association of Nrf2 with airway path-
ogenesis: lessons learned from genetic mouse models. Arch. Toxicol. 89,
1931–1957.
Chorley, B.N., Campbell, M.R., Wang, X., Karaca, M., Sambandan, D., Ban-
gura, F., Xue, P., Pi, J., Kleeberger, S.R., and Bell, D.A. (2012). Identification
of novel NRF2-regulated genes by ChIP-seq: influence on retinoid X receptor
alpha. Nucleic Acids Res. 40, 7416–7429.
Dobin, A., Davis, C.A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut,
P., Chaisson,M., andGingeras, T.R. (2013). STAR: ultrafast universal RNA-seq
aligner. Bioinformatics 29, 15–21.
Dubois, P.C., Trynka, G., Franke, L., Hunt, K.A., Romanos, J., Curtotti, A.,
Zhernakova, A., Heap, G.A., Ada´ny, R., Aromaa, A., et al. (2010). Multiple com-
mon variants for celiac disease influencing immune gene expression. Nat.
Genet. 42, 295–302.
ENCODE Project Consortium (2012). An integrated encyclopedia of DNA ele-
ments in the human genome. Nature 489, 57–74.
Farh, K.K., Marson, A., Zhu, J., Kleinewietfeld, M., Housley, W.J., Beik, S.,
Shoresh, N., Whitton, H., Ryan, R.J., Shishkin, A.A., et al. (2015). Genetic
and epigenetic fine mapping of causal autoimmune disease variants. Nature
518, 337–343.
Fogarty, M.P., Cannon, M.E., Vadlamudi, S., Gaulton, K.J., and Mohlke, K.L.
(2014). Identification of a regulatory variant that binds FOXA1 and FOXA2 at
the CDC123/CAMK1D type 2 diabetes GWAS locus. PLoS Genet. 10,
e1004633.
Gibbs, J.R., van der Brug, M.P., Hernandez, D.G., Traynor, B.J., Nalls, M.A.,
Lai, S.L., Arepalli, S., Dillman, A., Rafferty, I.P., Troncoso, J., et al. (2010).
Abundant quantitative trait loci exist for DNAmethylation and gene expression
in human brain. PLoS Genet. 6, e1000952.
Grundberg, E., Small, K.S., Hedman, A.K., Nica, A.C., Buil, A., Keildson, S.,
Bell, J.T., Yang, T.P., Meduri, E., Barrett, A., et al.; Multiple Tissue Human
Expression Resource (MuTHER) Consortium (2012). Mapping cis- and trans-
regulatory effects across multiple tissues in twins. Nat. Genet. 44, 1084–1089.
GTEx Consortium (2015). Human genomics. The Genotype-Tissue Expression
(GTEx) pilot analysis: multitissue gene regulation in humans. Science 348,
648–660.Hayes, J.D., and McMahon, M. (2001). Molecular basis for the contribution of
the antioxidant responsive element to cancer chemoprevention. Cancer Lett.
174, 103–113.
Hayes, J.D., and Dinkova-Kostova, A.T. (2014). The Nrf2 regulatory network
provides an interface between redox and intermediary metabolism. Trends
Biochem. Sci. 39, 199–218.
Ho¨glinger, G.U., Melhem, N.M., Dickson, D.W., Sleiman, P.M.A., Wang, L.S.,
Klei, L., Rademakers, R., de Silva, R., Litvan, I., Riley, D.E., et al.; PSPGenetics
Study Group (2011). Identification of common variants influencing risk of the
tauopathy progressive supranuclear palsy. Nat. Genet. 43, 699–705.
Hybertson, B.M., and Gao, B. (2014). Role of the Nrf2 signaling system in
health and disease. Clin. Genet. 86, 447–452.
Itoh, K., Chiba, T., Takahashi, S., Ishii, T., Igarashi, K., Katoh, Y., Oyake, T.,
Hayashi, N., Satoh, K., Hatayama, I., et al. (1997). An Nrf2/small Maf hetero-
dimer mediates the induction of phase II detoxifying enzyme genes through
antioxidant response elements. Biochem. Biophys. Res. Commun. 236,
313–322.
Ittner, A., Ke, Y.D., van Eersel, J., Gladbach, A., Go¨tz, J., and Ittner, L.M.
(2011). Brief update on different roles of tau in neurodegeneration. IUBMB
Life 63, 495–502.
Johnson, D.A., and Johnson, J.A. (2015). Nrf2-a therapeutic target for the
treatment of neurodegenerative diseases. Free Radic. Biol. Med. 88, 253–267.
Jun, G., Ibrahim-Verbaas, C.A., Vronskaya, M., Lambert, J.C., Chung, J., Naj,
A.C., Kunkle, B.W., Wang, L.S., Bis, J.C., Bellenguez, C., et al.; IGAP Con-
sortium (2016). A novel Alzheimer disease locus located near the gene encod-
ing tau protein. Mol. Psychiatry 21, 108–117.
Karczewski, K.J., Dudley, J.T., Kukurba, K.R., Chen, R., Butte, A.J., Montgom-
ery, S.B., and Snyder, M. (2013). Systematic functional regulatory assessment
of disease-associated variants. Proc. Natl. Acad. Sci. USA 110, 9607–9612.
Kouri, N., Ross, O.A., Dombroski, B., Younkin, C.S., Serie, D.J., Soto-Ortolaza,
A., Baker, M., Finch, N.C., Yoon, H., Kim, J., et al. (2015). Genome-wide asso-
ciation study of corticobasal degeneration identifies risk variants shared with
progressive supranuclear palsy. Nat. Commun. 6, 7247.
Kundaje, A., Meuleman, W., Ernst, J., Bilenky, M., Yen, A., Heravi-Moussavi,
A., Kheradpour, P., Zhang, Z., Wang, J., Ziller, M.J., et al.; Roadmap
Epigenomics Consortium (2015). Integrative analysis of 111 reference human
epigenomes. Nature 518, 317–330.
Li, H., Ruan, J., and Durbin, R. (2008). Mapping short DNA sequencing reads
and calling variants using mapping quality scores. Genome Res. 18, 1851–
1858.
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G.,
Abecasis, G., and Durbin, R.; 1000 Genome Project Data Processing Sub-
group (2009). The sequence alignment/map format and SAMtools. Bioinfor-
matics 25, 2078–2079.
Li, Q., Brown, J.B., Huang, H., and Bickel, P.J. (2011). Measuring reproduc-
ibility of high-throughput experiments. Ann. Appl. Stat. 5, 1752–1779.
Machanick, P., and Bailey, T.L. (2011). MEME-ChIP: motif analysis of large
DNA datasets. Bioinformatics 27, 1696–1697.
Maurano, M.T., Humbert, R., Rynes, E., Thurman, R.E., Haugen, E., Wang, H.,
Reynolds, A.P., Sandstrom, R., Qu, H., Brody, J., et al. (2012). Systematic
localization of common disease-associated variation in regulatory DNA.
Science 337, 1190–1195.
McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky,
A., Garimella, K., Altshuler, D., Gabriel, S., Daly, M., and DePristo, M.A. (2010).
The Genome Analysis Toolkit: a MapReduce framework for analyzing next-
generation DNA sequencing data. Genome Res. 20, 1297–1303.
Muramatsu, H., Katsuoka, F., Toide, K., Shimizu, Y., Furusako, S., and Yama-
moto, M. (2013). Nrf2 deficiency leads to behavioral, neurochemical and tran-
scriptional changes in mice. Genes Cells 18, 899–908.
Myers, A.J., Gibbs, J.R., Webster, J.A., Rohrer, K., Zhao, A., Marlowe, L.,
Kaleem, M., Leung, D., Bryden, L., Nath, P., et al. (2007). A survey of genetic
human cortical gene expression. Nat. Genet. 39, 1494–1499.Cell Reports 15, 830–842, April 26, 2016 841
Nioi, P., McMahon, M., Itoh, K., Yamamoto, M., and Hayes, J.D. (2003). Iden-
tification of a novel Nrf2-regulated antioxidant response element (ARE) in the
mouse NAD(P)H:quinone oxidoreductase 1 gene: reassessment of the ARE
consensus sequence. Biochem. J. 374, 337–348.
Ramasamy, A., Trabzuni, D., Gibbs, J.R., Dillman, A., Hernandez, D.G., Are-
palli, S., Walker, R., Smith, C., Ilori, G.P., Shabalin, A.A., et al.; NABEC; UKBEC
(2013). Resolving the polymorphism-in-probe problem is critical for correct
interpretation of expression QTL studies. Nucleic Acids Res. 41, e88.
Ramasamy, A., Trabzuni, D., Guelfi, S., Varghese, V., Smith, C., Walker, R., De,
T., Coin, L., de Silva, R., Cookson, M.R., et al.; UK Brain Expression
Consortium; North American Brain Expression Consortium (2014). Genetic
variability in the regulation of gene expression in ten regions of the human
brain. Nat. Neurosci. 17, 1418–1428.
Rushmore, T.H., Morton, M.R., and Pickett, C.B. (1991). The antioxidant
responsive element. Activation by oxidative stress and identification of the
DNA consensus sequence required for functional activity. J. Biol. Chem.
266, 11632–11639.
Schaub, M.A., Boyle, A.P., Kundaje, A., Batzoglou, S., and Snyder, M. (2012).
Linking disease associations with regulatory information in the human
genome. Genome Res. 22, 1748–1759.
Spencer, C.C.A., Plagnol, V., Strange, A., Gardner, M., Paisan-Ruiz, C., Band,
G., Barker, R.A., Bellenguez, C., Bhatia, K., Blackburn, H., et al. (2011). Dissec-
tion of the genetics of Parkinson’s disease identifies an additional association
50 of SNCA andmultiple associated haplotypes at 17q21. Hum.Mol. Genet. 20,
345–353.
Stack, C., Jainuddin, S., Elipenahli, C., Gerges, M., Starkova, N., Starkov, A.A.,
Jove´, M., Portero-Otin, M., Launay, N., Pujol, A., et al. (2014). Methylene blue
upregulates Nrf2/ARE genes and prevents tau-related neurotoxicity. Hum.
Mol. Genet. 23, 3716–3732.
Stefansson, H., Helgason, A., Thorleifsson, G., Steinthorsdottir, V., Masson,
G., Barnard, J., Baker, A., Jonasdottir, A., Ingason, A., Gudnadottir, V.G.,
et al. (2005). A common inversion under selection in Europeans. Nat. Genet.
37, 129–137.
Tong, K.I., Kobayashi, A., Katsuoka, F., and Yamamoto, M. (2006). Two-site
substrate recognition model for the Keap1-Nrf2 system: a hinge and latch
mechanism. Biol. Chem. 387, 1311–1320.
Trabzuni, D., Ryten,M.,Walker, R., Smith, C., Imran, S., Ramasamy, A.,Weale,
M.E., and Hardy, J. (2011). Quality control parameters on a large dataset of
regionally dissected human control brains for whole genome expression
studies. J. Neurochem. 119, 275–282.842 Cell Reports 15, 830–842, April 26, 2016Trabzuni, D., Wray, S., Vandrovcova, J., Ramasamy, A., Walker, R., Smith, C.,
Luk, C., Gibbs, J.R., Dillman, A., Hernandez, D.G., et al. (2012). MAPT expres-
sion and splicing is differentially regulated by brain region: relation to genotype
and implication for tauopathies. Hum. Mol. Genet. 21, 4094–4103.
Wakabayashi, N., Dinkova-Kostova, A.T., Holtzclaw, W.D., Kang, M.I.,
Kobayashi, A., Yamamoto, M., Kensler, T.W., and Talalay, P. (2004). Protection
against electrophile and oxidant stress by induction of the phase 2 response:
fate of cysteines of the Keap1 sensor modified by inducers. Proc. Natl. Acad.
Sci. USA 101, 2040–2045.
Wang, X., Tomso, D.J., Chorley, B.N., Cho, H.Y., Cheung, V.G., Kleeberger,
S.R., and Bell, D.A. (2007). Identification of polymorphic antioxidant response
elements in the human genome. Hum. Mol. Genet. 16, 1188–1200.
Ward, L.D., and Kellis, M. (2012). HaploReg: a resource for exploring chro-
matin states, conservation, and regulatory motif alterations within sets of
genetically linked variants. Nucleic Acids Res. 40, D930–D934.
Wasserman, W.W., and Fahl, W.E. (1997). Functional antioxidant responsive
elements. Proc. Natl. Acad. Sci. USA 94, 5361–5366.
Welter, D., MacArthur, J., Morales, J., Burdett, T., Hall, P., Junkins, H., Klemm,
A., Flicek, P., Manolio, T., Hindorff, L., and Parkinson, H. (2014). The NHGRI
GWAS Catalog, a curated resource of SNP-trait associations. Nucleic Acids
Res. 42, D1001–D1006.
Yamazaki, H., Tanji, K., Wakabayashi, K., Matsuura, S., and Itoh, K. (2015).
Role of the Keap1/Nrf2 pathway in neurodegenerative diseases. Pathol. Int.
65, 210–219.
Zeron-Medina, J., Wang, X., Repapi, E., Campbell, M.R., Su, D., Castro-Giner,
F., Davies, B., Peterse, E.F., Sacilotto, N., Walker, G.J., et al. (2013). A poly-
morphic p53 response element in KIT ligand influences cancer risk and has
undergone natural selection. Cell 155, 410–422.
Zhang, Y., Liu, T., Meyer, C.A., Eeckhoute, J., Johnson, D.S., Bernstein, B.E.,
Nusbaum, C., Myers, R.M., Brown, M., Li, W., and Liu, X.S. (2008). Model-
based analysis of ChIP-seq (MACS). Genome Biol. 9, R137.
Zhong, Q., Congdon, E.E., Nagaraja, H.N., and Kuret, J. (2012). Tau isoform
composition influences rate and extent of filament formation. J. Biol. Chem.
287, 20711–20719.
Zou, F., Chai, H.S., Younkin, C.S., Allen, M., Crook, J., Pankratz, V.S., Carra-
squillo, M.M., Rowley, C.N., Nair, A.A., Middha, S., et al.; Alzheimer’s Disease
Genetics Consortium (2012). Brain expression genome-wide association
study (eGWAS) identifies human disease-associated variants. PLoS Genet.
8, e1002707.
